Table 2.

Non-human primate studies on the use of bnAbs to target, control and potentially eliminate the viral reservoir.

	SHIV	ART initiation	BnAb	Additional Interventions	Outcome
Nishimura et al. (67)	SHIVAD8-EO	No ART	3BNC117 + 10-1074 at days 3, 10 and 17 PI		Viral control in 3 of 6 animals from intra-rectal and 3 of 7 animals from intravenous inoculation
Nishimura et al. (68)	SHIVAD8-EO	2 weeks post infection	3BNC117 + 10-1074 alone at weeks 2, 4 and 6 PI or ART initiation at week 2; 3BNC117 + 10-1074 at weeks 9, 11 and 13; ART discontinuation at week 10		Viral control in 4 of 6 animals in bnAb alone arm in 3 of 6 animals in bnAb and ART arm
Borducchi et al. (69)	SHIVSF162P3	7 days post infection	PGT121	TLR7 agonist	No rebound in 5/11 animals and delay in rebound when compared to controls (112 vs 21 days)
Hsu et al. (70)	SHIV1157ipd3N4	2 weeks post infection	PGT121 + N6-LS	TLR7 agonist	Delay in rebound when compared to controls (6 versus 3 weeks)
Barouch et al. (71)	SHIVSF162P3	12 months post infection	PGT121 or its FC modified version (GS9721)	TLR7 agonist	No rebound in 7/17 animals
Whitney et al. (72)	SHIVAD8	~50 days post infection	3BNC117 + 10-1074	IL-15 superagonist	No difference in time to rebound. Post-rebound control in 6 of 8 animals
Barouch et al. (73)	SHIVSF162P3	9 days post infection	PGT121	TLR7 agonist, Ad26/MVA vaccine	4 of 12 PGT121+TLR7 agonisttreated animals and 4 of 10 Ad26/MVA vaccine+PGT121+TLR7 agonist-treated animals did not rebound post treatment interruption. Only 4 of 10 Ad26/MVA vaccine+PGT121+TLR7 agonist-treated animals remained viremic 140 days post treatment interruption.